Atai life sciences announces completion of phase 1 study of vls-01 in healthy participants

New york and berlin, oct. 02, 2023 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the completion of the phase 1 study of vls-01 in healthy participants.

ATAI Ratings Summary

ATAI Quant Ranking